Quick Answer
Disc Medicine, Inc. reported Cash and Equivalents of $91.14 million for fiscal year 2025.
Disc Medicine, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $91.14M | -52.6% |
| 2024 | $192.43M | -46.6% |
| 2023 | $360.38M | +85.2% |
| 2022 | $194.61M | +121.1% |
| 2021 | $88.04M | +1855.1% |
| 2020 | $4.50M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $140.66M | -27.0% | +10.5% |
| June 30, 2025 | $127.34M | -54.6% | +3.8% |
| March 31, 2025 | $122.67M | -64.2% | -36.3% |
| December 31, 2024 | $192.43M | -46.6% | -0.1% |
| September 30, 2024 | $192.64M | -48.0% | -31.4% |
| June 30, 2024 | $280.66M | -25.7% | -18.1% |
| March 31, 2024 | $342.62M | +44.9% | -4.9% |
| December 31, 2023 | $360.38M | +85.2% | -2.7% |
- Disc Medicine, Inc. showed a decrease of -52.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Disc Medicine, Inc.’s cash and equivalents has grown by 1924.1% (from $4.50 million to $91.14 million).
- The most recent figure is from Disc Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: